Emerging role of topotecan in first-line therapy of small-cell lung cancer

Clinical Lung Cancer

Volumn 4, Issue 5, 2003, Pages 279-287

  Greco, F Anthony ^a   Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Brain metastases; Carboplatin; Cisplatin; Etoposide; Lung cancer; Myelosuppression

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; VINCRISTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; IN VITRO STUDY; LUNG SMALL CELL CANCER; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT CARE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038748028     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.007     Document Type: Review

References (66)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002; 23:225-239.
3. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(suppl 1):3-13.
4. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
5. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Ontology Group Trial. J Clin Oncol 1996; 14:2345-2352.
6. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-2096.
7. Eckardt J, Gralla R, Palmer MC, et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996; 7(suppl 5):107.
8. Jonsson E, Fridborg H, Nygren P, et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998; 54:509-514.
9. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88:734-741.
10. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc Am Assoc Cancer Res 1992; 33:431 (Abstract #2573).
11. Whitacre CM, Zborowska E, Gordon NH, et al. Topotecan increases topoisomerase II levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997; 57:1425-1428.
12. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14:3074-3084.
13. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study [abstract]. Lung Cancer 1997; 18(suppl 1):35.
14. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-656.
15. Wall JG, Burris HA III, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3:337-345.
16. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
17. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999; 22:517-522.
18. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89:577-580.
19. Schnell FM, Birch R, Sysel IA, et al. A phase I trial of combined paclitaxel and topotecan for extensive small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:281b (Abstract #2877).
20. Jacobs SA, Jett JR, Belani CP, et al. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18:470a (Abstract #1814).
21. Tweedy CR, Andrews DF, Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc Am Soc Clin Oncol 1999; 18:525a (Abstract #2025).
22. Schütte W, Bork I, Öhlmann K, et al. Phase II study: first line treatment of stage IV small cell lung cancer with topotecan and paclitaxel. Proc Am Soc Clin Oncol 2001; 20:283b (Abstract #2882).
23. Jett JR, Day R, Levitt M, et al. Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 1997; 18:13 (Abstract #38).
24. Lynch TJ, Herndon JE, Lyss AP, et al. Paclitaxel (P) topotecan (T) + GCSF for previously untreated extensive small cell lung cancer (E-SCLC): preliminary analysis of Cancer and Leukemia Group B (CALGB) 9430. Proc Am Soc Clin Oncol 2000; 19:491a (Abstract #1922).
25. Jett JR, Bernath AM Jr, Hillman SL, et al. Oral topotecan and paclitaxel with G-CSF support in patients with untreated extensive stage small cell (ED-SCLC): a phase II trial of the NCCTG. Proc Am Soc Clin Oncol 2002; 21:326a (Abstract #1301).
26. Miller AA, Lilenbaum RC, Lynch TJ, et al. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 1996; 14:1964-1965.
27. Lyss AP, Herndon JE, Bogart JE, et al. Topotecan (Topo) + paclitaxel (Tax) + G-CSF (G) induction followed by concurrent chemoradiotherapy (CCRT) for patients (pts) with limited stage small cell lung cancer (L-SCLC): preliminary analysis of CALGB 39808. Proc Am Soc Clin Oncol 2001; 20:318a (Abstract #1270).
28. Dediu M, Radut M, Crisan E, et al. Topotecan (T) and fractionated cisplatin (CDDP) as first line chemotherapy for extensive small cell lung cancer (E-SCLC): a phase I/II study. Proc Am Soc Clin Oncol 2000; 19:533a (Abstract #2096).
29. Seifart U, Jensen K, Ukena D, et al. Topotecan (T) cisplatin (DDP) 3 days versus topotecan/cisplatin 5 days in patients with metastatic small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2001; 20:319a (Abstract #1272).
30. Pujol JL, von Pawel J, Tumolo S, et al. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small cell lung cancer. Oncology 2001; 61 (suppl 1):47-54.
31. Bowman A, Rye T, Ross G, et al. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. J Clin Oncol 2001; 19:3255-3259.
32. Faucette SR, McCune JS, Donahue AE, et al. Impact of carboplatin (C) sequence on myelosuppression and systemic exposure of topotecan (T) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1999; 18:210a (Abstract #807).
33. Bolis G, Sarfone G, Sciatta C, et al. A phase II study of topotecan (T), carboplatin (C) and paclitaxel (P) as front line treatment in suboptimal advanced epithelial ovarian cancer (AEOC). Proc Am Soc Clin Onol 2000; 19:390a (Abstract #1543).
34. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
35. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86:1517-1524.
36. Thompson D, Hainsworth JD, Burris HA, et al. A phase I trial of topotecan, paclitaxel, and carboplatin with or without growth factor support. Proc Am Soc Clin Oncol 1999; 18:230a. (Abstract #886).
37. Hainsworth JD, Morrissey LH, Scullin DC Jr, et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002; 94:2426-2433.
38. Frasci G, Nicolella G, Comella P, et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Br J Cancer 2001; 84:1166-1171.
39. Dunphy F, Hesketh P, Chansky K, et al. Southwest Oncology Group trial (SWOG) 9914: phase II trial of paclitaxel, carboplatin and topotecan (PCT) in untreated patients (pts) with extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2002; 21:297a (Abstract #1184).
40. Hainsworth JD, Morrissey LH, Scullin DC Jr., et al. Paclitaxel, carboplatin, and topotecan in the treatment of small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002; 94:2426-2433.
41. Hainsworth JD, Burris HA III, Greco FA. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Semin Oncol 2001; 28:43-47.
42. Gillenwater HH, McCune JS, Donahue AE, et al. Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC). Proc Am Soc Clin Oncol 2000; 19:533a (Abstract #2097).
43. Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996; 39:109-112.
44. Buchholz E, Manegold C, Drings P, et al. Sequential administration of topotecan (topo) and etoposide (ETO) in extensive small cell lung cancer: a phase I study. Proc Am Soc Clin Oncol 1998; 17:479a (Abstract #1843).
45. O'Neill P, Clark PI, Smith D, et al. A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology 2001; 61(suppl 1):25-29.
46. Gervais R, Quoix E, Mattson K, et al. Randomised phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC). Lung Cancer 2000; 29(suppl 1):50 (Abstract #163).
47. Gervais R, Quoix E, Breton JL, et al. Randomised phase II study of topotecan/cisplatin (TC) versus topotecan/etoposide (TE) in patients with untreated, extensive disease, small-cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:318a (Abstract #1268).
48. Smith MJ, Spencer SA, Zhang R, et al. Phase I/IIa study of sequential ifosfamide (I) and topotecan (T) in patients with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 17:500a (Abstract #1927).
49. Murren J, Kraut E, Balcerzak S, et al. Phase II trial of topotecan and cyclophosphamide (CY) with G-CSF in high-risk small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 17:495a (Abstract #1907).
50. Ventriglia M, Cabrera L, Maidana M, et al. A phase II trial of topotecan (Hycamtin®) with ifosfamide (Duvaxan®) plus mesna (Mesnex®) as first line treatment in patients (pts) with small cell lung cancer (SCLC): a preliminary report. Lung Cancer 2000; 29(suppl 1 :67 (Abstract #218).
51. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:2114-2122.
52. Miller AA, Niell HB. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. Lung Cancer 2001; 33:241-248.
53. Felip E, Font A, Rosell R, et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive small-cell lung cancer (SCLC): a Spanish Lung Cancer Group phase II study. Proc Am Soc Clin Oncol 2001; 20:319a (Abstract #1271).
54. Mavroudis D, Pavlakou G, Veslemes M, et al. A phase II study of the sequential administration of cisplatin-etoposide and topotecan in patients with extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2001; 20:283b (Abstract #2885).
55. Jett J, Hatfield A, Bauman M, et al. Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 2000; 19:491a (Abstract #1921).
56. Vassilis G, Veslemes M, Palamidas P, et al. A phase II study alternating cisplatin-etoposide and topotecan administered in patients with extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2001; 20:318a (Abstract #1269).
57. Sorensen M, Jensen PB, Herrstedt J, et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol 2000; 11:829-835.
58. Johnson DH, Hainsworth JD, Hande KR, et al. Combination chemotherapy with oral etoposide. Semin Oncol 1992; 19:19-24.
59. Bertrand R, O'Connor PM, Kerrigan D, et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992; 28A:743-748.
60. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 1999; 10:753-759.
61. Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996; 37:195-202.
62. Schütte W, Manegold C, von Pawel JV, et al. Topotecan-a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 1999; 33:354-363.
63. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study. Eur J Cancer 2002; 38:1724-1729.
64. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001; 83:394-399.
65. Morris RT, Munkarah A, Field J, et al. Phase II trial of weekly topotecan in patients with potentially platinum sensitive relapsed ovarian and peritoneal cancer. Proc Am Soc Clin Oncol 2002; 21:173b (Abstract #2512).
66. Mattern MR, Hofmann GA, McCabe FL, et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991; 51:5813-5816.